ArdorComm Media Group

treatment

Saudi Arabia Reports Three New MERS Cases, Highlighting Risks and Differences from COVID-19

News on Health 1 ArdorComm Media Group Saudi Arabia Reports Three New MERS Cases, Highlighting Risks and Differences from COVID-19

The Saudi health ministry has notified the World Health Organization (WHO) of three new Middle East Respiratory Syndrome (MERS) coronavirus cases in Riyadh, Saudi Arabia. Sadly, one of these cases resulted in death. All three individuals were male, aged between 56 and 60, with pre-existing health conditions. None of them were healthcare workers. This brings the total number of MERS cases reported in Saudi Arabia in 2024 to four, with two fatalities. Dr. Syed Abdul Aleem, a Pulmonology Consultant at CARE Hospitals in Musheerabad, Hyderabad, explains that MERS-CoV is a viral respiratory illness caused by the MERS strain of coronavirus. Unlike COVID-19, MERS tends to be more severe with a higher mortality rate but is less contagious. It is primarily transmitted from camels to humans, with limited human-to-human transmission. Risk factors for MERS-CoV include close contact with camels or living in endemic regions, along with underlying medical conditions such as diabetes or chronic lung disease. Symptoms are similar to COVID-19, including fever, cough, and shortness of breath, but MERS can progress to severe respiratory illness, leading to pneumonia and acute respiratory distress syndrome (ARDS). Some individuals may also experience gastrointestinal symptoms like diarrhea. Management involves supportive care, with severe cases requiring hospitalization and supportive measures like supplemental oxygen therapy and mechanical ventilation. There is no specific antiviral treatment for MERS, but prevention measures include avoiding close contact with camels, practicing good hand hygiene, and avoiding contact with sick individuals. This highlights the importance of understanding the differences between MERS and COVID-19 and taking appropriate precautions to prevent transmission and manage cases effectively.  

Health Ministry Issues Alert on Covid-19 Subvariant JN.1: Guidelines and Concerns Amid Rising Cases

News on health 4 ArdorComm Media Group Health Ministry Issues Alert on Covid-19 Subvariant JN.1: Guidelines and Concerns Amid Rising Cases

The Indian government has issued an alert to states regarding the emergence of the new Covid-19 subvariant, JN.1, as cases continue to rise in Kerala and 15 cases have been detected in samples from Goa. The Health Ministry emphasized that it is not yet clear whether an infection caused by JN.1 produces different symptoms or is more severe than other variants. The ministry stated that there is currently no indication of increased severity from JN.1, and there is no evidence that it presents an increased risk to public health compared to other circulating variants. Experts, including Dr. GC Khilnani, reassured that the elderly and those with comorbidities are not at an increased risk compared to other variants. General precautions such as handwashing and avoiding crowded areas during the festive season are recommended. The existing treatment for COVID-19 is expected to be effective against JN.1, and updated COVID-19 vaccines are expected to provide increased protection. RT-PCR tests remain the most reliable method for detecting the new subvariant. As the festive season approaches, the Health Ministry stressed the importance of adhering to respiratory hygiene norms, including wearing masks in enclosed and crowded spaces, frequent handwashing, and social distancing. States, such as Karnataka, are taking additional measures, mandating face masks for the elderly and those with comorbidities. The Health Ministry is conducting intensified surveillance at various levels, including laboratories, communities, and sewage, to monitor and report cases of influenza-like illness and Severe Acute Respiratory Illness. The global concern over JN.1 is due to its immunity-evading capacity, leading to rapid spread, with outbreaks reported in the US, China, and Singapore. JN.1 is a descendant of the BA.2.86 lineage of SARS-CoV-2.